A randomized comparison of acute thrombogenecity and long-term vascular healing between biodegradable-polymer (BP) versus durable polymer (DP) everolimus-eluting stents in acute ST-elevation myocardial infarction - CONNECT Study

Tokorozawa Heart Center Clinical trial unit0 个研究点目标入组 240 人开始时间: 2017年5月20日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1.Female ofchildbearing potential (age < 50 years and last menstruation within the last 12 months), who did not undergo tubal ligation, ovariectomy or hysterectomy. 2.Known intolerance to aspirin, clopidogrel, prasugrel, ticagrelor, heparin, stainless steel, cobalt chromium, platinum chromium, everolimus or contrast material 3.Inability to understand and provide informed consent 4.Currently participating in another trial before reaching first endpoint 5.Mechanical complications of acute myocardial infarction 6.Acute myocardial infarction secondary to stent thrombosis or restenosis 7.Planned surgery within 6 months of PCI unless dual antiplatelet therapy is maintained throughout the peri-surgical period 8.Noncardiac comorbid conditions are present with life expectancy <3years or that may result in protocol noncompliance 9.History of bleeding diathesis or known coagulopathy 10.Use of oral anticoagulation 11.Age >=90 years 12.LV-function at index procedure <=20% 13.Cancer under active treatment (chemotherapy) 14.Hemodynamic instability following primary PCI 15.Chronic kidey disease (Creatinine - Clearance < 30ml/min) 16.OCT technically not feasible (severe calcification, tortuosity)

发起方

Tokorozawa Heart Center Clinical trial unit